First Time Loading...

G1 Therapeutics Inc
NASDAQ:GTHX

Watchlist Manager
G1 Therapeutics Inc Logo
G1 Therapeutics Inc
NASDAQ:GTHX
Watchlist
Price: 4.44 USD 7.51%
Updated: May 3, 2024
Section:
 

Wall Street
Price Targets

GTHX Price Targets Summary
G1 Therapeutics Inc

Wall Street analysts forecast GTHX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GTHX is 8.67 USD with a low forecast of 5.05 USD and a high forecast of 12.6 USD.

GTHX Lowest Forecast
Wall Street Target
5.05 USD
14% Upside
GTHX Average Forecast
Wall Street Target
8.67 USD
95% Upside
GTHX Highest Forecast
Wall Street Target
12.6 USD
184% Upside
Lowest
Price Target
5.05 USD
14% Upside
Average
Price Target
8.67 USD
95% Upside
Highest
Price Target
12.6 USD
184% Upside
G1 Therapeutics Inc Competitors:
Price Targets
MRUS
Merus NV
31% Upside
CPRX
Catalyst Pharmaceuticals Inc
80% Upside
DNLI
Denali Therapeutics Inc
150% Upside
HARP
Harpoon Therapeutics Inc
8% Upside
MRUS
Merus NV
31% Upside
CPRX
Catalyst Pharmaceuticals Inc
80% Upside
DNLI
Denali Therapeutics Inc
150% Upside
HARP
Harpoon Therapeutics Inc
8% Upside
ADAG
Adagene Inc
408% Upside
I
IMRX
Immuneering Corp
752% Upside
ABIO
ARCA Biopharma Inc
115% Upside
TRDA
Entrada Therapeutics Inc
58% Upside

Revenue
Forecast

Revenue Estimate
G1 Therapeutics Inc

For the last 8 years the compound annual growth rate for G1 Therapeutics Inc's revenue is 88%. The projected CAGR for the next 3 years is 18%.

88%
Past Growth
18%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
G1 Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
G1 Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-30%
Average Miss
What are analyst estimates?

See Also

Summary
GTHX intrinsic value, competitors valuation, and company profile.
DCF Valuation
GTHX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GTHX stock valuation using valuation multiples.
Wall Street Estimates
GTHX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GTHX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GTHX's stock price target?
Price Target
8.67 USD

According to Wall Street analysts, the average 1-year price target for GTHX is 8.67 USD with a low forecast of 5.05 USD and a high forecast of 12.6 USD.

What is G1 Therapeutics Inc's Revenue forecast?
Projected CAGR
18%

For the last 8 years the compound annual growth rate for G1 Therapeutics Inc's revenue is 88%. The projected CAGR for the next 3 years is 18%.

ALPHA SPREAD
Join more than 133,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.